The UMCC has had ever continuing growth in its scientific and clinical relationships with CALGB. UMCC faculty participate in administrative, scientific, committee and planning activities within the CALGB. The UMCC faculty design, conduct and chair many groups studies and enter large numbers of patients (pts.) onto CALGB protocols. UMCC faculty chair two major committees within the group and are the responsible investigators for a large number of studies. Funding to continue and expand these activities will allow for further strong participation of UMCC in groupwide studies. For example, UMCC inhouse phase I (2 to 4 per year) studies frequently evolve into groupwide phase II studies. UMCC also conducts pilot studies which have formed the conceptual bases for groupwide studies. UMCC is the single largest accruing institution for pts. with acute leukemia and the basic science laboratories studying this disease is a valuable resource to the group. These specialized laboratories include cytogenetics and pharmacology which serve as a resource for collaborative efforts and innovative bases for future CALGB interactive laboratory/clinical studies. UMCC and its collaborating institutions (VA Medical Center - Baltimore; Medical Center of Delaware CCOP), and Greater Baltimore Medical Center) propose to further increment accrual beyond 250 protocol entries per year onto CALGB studies. This accrual is one of the largest in the group. Participation in CALGB studies will allow UMCC and its collaborating physicians greater treatment options for pts. with diseases under study by the group. UMCC currently enters pts. onto trials in acute leukemia, small cell lung cancer, breast cancer, and lymphoma. Ancillary studies are evaluating cellular pharmacology and sensitivity of Ara-C as well as the cytogenetics of leukemia cells utilizing standard and methotrexate synchronized resolution techniques. Many currently active CALGB groupwide studies are derived in part from pilot data from the UMCC including studies in acute leukemia, breast cancer, and small cell lung cancer and UMCC laboratories will provide pharmacology support for these hormone studies. Funded basic science laboratories such as those studying small cell lung cancer biology and growth modulation act as group resources for interactive laboratory clinical trials. UMCC pilot studies in hormonal treatment of breast cancer have opened up a new area of treatment for the group in breast cancer. UMCC also participates in selected CALGB phase II studies as well as uncommon tumors entered onto intergroup studies through CALGB. This grant will allow UMCC to continue to enter pts. onto CALGB studies and continue to provide a strong scientific input into the group science and group administrative activities. This grant will also allow for the continuation of meritorious pilot protocols and will allow UMCC to monitor and collect data which will produce mutual benefit to the UMCC and the CALGB.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA031983-07
Application #
3557209
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-04-01
Project End
1993-03-31
Budget Start
1988-04-01
Budget End
1989-03-31
Support Year
7
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Lewis, Lionel D; Miller, Antonius A; Owzar, Kouros et al. (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 23:29-33
Jaklitsch, Michael T; Gu, Lin; Demmy, Todd et al. (2013) Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. J Thorac Cardiovasc Surg 146:9-16
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Boylan, Alice M; Wang, Xiaofei F; Ko, Richard et al. (2013) Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. J Thorac Cardiovasc Surg 146:206-11
Edelman, Martin J; Shvartsbeyn, Marianna (2012) Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance. Clin Lung Cancer 13:171-80

Showing the most recent 10 out of 102 publications